Isogenica
Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on our proprietary fully synthetic antibody libraries and leveraging our CIS Display and Colibra™ technologies to accelerate the discovery.
Specialties
Isogenica’s massive synthetic libraries are most optimally screened for antibody binders against soluble proteins or membrane targets (cell-based selections) using the company’s proprietary CIS Display platform.
Contact Isogenica via their website
News archive
20/05/2021 Isogenica announces Dr William (Bill) Eldridge promotion to Chief Scientific Officer...more
18/01/2021 Isogenica-Aro collaboration goes from strength to strength...more
08/12/2020 Isogenica Opens Pre-doc Program...more
30/11/2020 Isogenica publishes whitepaper on VHH in T cell redirection...more
30/11/2020 Isogenica supports MRC iCASE PhD Award...more
28/10/2020 Register for Isogenica's CAR-T webcast 25th November...more
02/06/2020 Meet Isogenica at PEGS Boston and BIO Digital...more
04/11/2019 Meet Isogenica at BIO-Europe and PEGS Summit Europe this month...more
15/10/2019 Dr Bjӧrn Cochlovius appointed to Isogenica’s Board of Directors...more
12/09/2019 Isogenica appoints Dr David Mead as Director of Business Development...more
12/08/2019 Isogenica joins the BioPartnership Programme
